tirzepatide shortage fda update says of GLP-1 drug is over The FDA says the Zepbound

Oct 8 2020;9(10)doi:10.3390/cells9102253

Several clinical trials utilizing imaging-based assessments have demonstrated significant reductions in visceral fat volume among patients treated with GLP-1 agonists

Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis

Wegovy contains semaglutide, the same active ingredient as Ozempic and Rybelsus

They don't change the physical size of your stomach

Storage conditions directly affect potency, and degraded semaglutide can deliver less active compound per milligram than the label states